<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01907594</url>
  </required_header>
  <id_info>
    <org_study_id>6769</org_study_id>
    <nct_id>NCT01907594</nct_id>
  </id_info>
  <brief_title>Effects of Nicotine Replacement Therapy and D-cycloserine on Nicotine Treatment Seekers</brief_title>
  <official_title>Effects of Nicotine Replacement Therapy and D-cycloserine on Nicotine Treatment Seekers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>New York State Psychiatric Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>New York State Psychiatric Institute</source>
  <brief_summary>
    <textblock>
      The investigators previously developed a cigarette cue extinction treatment (CET) procedure&#xD;
      in non-treatment seeking volunteer smokers in our nicotine laboratory. The goal of Cue&#xD;
      Extinction Treatment is to un-pair a behavioral or autonomic response from the stimulus that&#xD;
      triggers it. This is accomplished through repeated exposure to that trigger, while removing&#xD;
      the patient's ability to act out the conditioned response. In the present study, the trigger&#xD;
      is a lit cigarette, and the response the investigators seek to un-pair is cigarette craving.&#xD;
      In the procedure the investigators have previously developed and intend to use again, the&#xD;
      participant is shown a pack of his brand of choice cigarettes. The researcher removes a&#xD;
      cigarette from the pack, lights it, and asks the participant to hold the cigarette without&#xD;
      smoking it for 90 seconds. This procedure is repeated seven times over the course of a&#xD;
      six-hour lab session. The investigators hope to boost the clinical response to smoking cue&#xD;
      exposure therapy in quitters on NRT (nicotine replacement therapy) pretreatment by&#xD;
      pharmacological augmentation with the partial NMDA receptor agonist D-cycloserine (DCS).&#xD;
      Behavioral extinction training is a form of learning that may be modulated by NMDA receptor&#xD;
      mediated glutamate transmission. The study's main hypothesis is that the partial NMDA&#xD;
      receptor agonist D-cycloserine (DCS) facilitates cue exposure training and may prevent&#xD;
      relapse to smoking. The aim of the proposed study is to assess whether DCS-facilitation of&#xD;
      cue-exposure therapy improves abstinence among smokers on the nicotine patch seeking&#xD;
      treatment. Development of an effective treatment strategy to enhance the effectiveness of&#xD;
      NRTs would have a direct and significant positive impact on public health.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Ran out of funding&#xD;
  </why_stopped>
  <start_date type="Actual">August 2013</start_date>
  <completion_date type="Actual">September 2016</completion_date>
  <primary_completion_date type="Actual">May 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Cigarettes Smoked</measure>
    <time_frame>3 months</time_frame>
    <description>Smoking Diary kept of daily cigarette smoking.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Cigarette Smoking</condition>
  <arm_group>
    <arm_group_label>D-cycloserine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The investigators will randomize participants to either DCS 250 mg or placebo, administered daily for four days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Gelatin Capsule</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>The investigators will randomize participants to either DCS 250 mg or placebo, administered daily for four days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>D-cycloserine</intervention_name>
    <arm_group_label>D-cycloserine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nicotine Replacement Therapy (patch)</intervention_name>
    <arm_group_label>D-cycloserine</arm_group_label>
    <arm_group_label>Gelatin Capsule</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Smoking Cue Exposure</intervention_name>
    <arm_group_label>D-cycloserine</arm_group_label>
    <arm_group_label>Gelatin Capsule</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Progressive Muscle Relaxation</intervention_name>
    <arm_group_label>D-cycloserine</arm_group_label>
    <arm_group_label>Gelatin Capsule</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>The investigators will administer Gelatin Capsule instead of D-Cycloserine in a double blind fashion to some of study subjects.</description>
    <arm_group_label>Gelatin Capsule</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Seeking treatment for nicotine dependence&#xD;
&#xD;
          2. Medically healthy on the basis of physical examination and medical history, vital&#xD;
             signs, EKG, and laboratory tests, with a negative pregnancy test for females.&#xD;
&#xD;
          3. A DSM-IV diagnosis of nicotine dependence with physiological dependence. Has smoked at&#xD;
             least 15 cigarettes daily for at least two years.&#xD;
&#xD;
          4. Able to perform study procedures.&#xD;
&#xD;
          5. Males or females between the ages of 21-55 yrs.&#xD;
&#xD;
          6. Female Participants agree to use an effective method of birth control&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. A DSM-IV diagnosis of lifetime history of abuse or dependence on alcohol or drugs&#xD;
             other than nicotine&#xD;
&#xD;
          2. Current Axis I diagnosis or current treatment with psychotropic medications (within&#xD;
             last three months).&#xD;
&#xD;
          3. Lifetime history of schizophrenia or other psychotic disorders, bipolar disorder, or&#xD;
             anxiety disorders.&#xD;
&#xD;
          4. Participants on parole or probation&#xD;
&#xD;
          5. History of significant recent violent behavior, e.g., one or more incidents of violent&#xD;
             behavior in the past year resulting in physical damage.&#xD;
&#xD;
          6. Unstable medical condition, Blood pressure &gt; 140/90, Pregnancy.&#xD;
&#xD;
          7. History of allergic reaction to nicotine patch.&#xD;
&#xD;
          8. History of hypersensitivity to cycloserine.&#xD;
&#xD;
          9. Any history of seizures&#xD;
&#xD;
         10. History of renal disease.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>S. Rob Vorel, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>New York State Psychiatric Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>New York State Psychiatric Institute</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>July 10, 2013</study_first_submitted>
  <study_first_submitted_qc>July 22, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 25, 2013</study_first_posted>
  <last_update_submitted>October 5, 2020</last_update_submitted>
  <last_update_submitted_qc>October 5, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 8, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>New York State Psychiatric Institute</investigator_affiliation>
    <investigator_full_name>S. Rob Vorel</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cycloserine</mesh_term>
    <mesh_term>Nicotine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

